Charles Schwab
SPRO icon

Charles Schwab’s Spero Therapeutics SPRO Stock Holding History

Charles Schwab’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.8K Hold
28,565
– – ﹤0.01% 3411
2025
Q4 		$66.6K Hold
28,565
– – ﹤0.01% 3414
2025
Q3 		$53.7K Hold
28,565
– – ﹤0.01% 3427
2025
Q2 		$82.8K Hold
28,565
– – ﹤0.01% 3422
2025
Q1 		$20.6K Hold
28,565
– – ﹤0.01% 3458
2024
Q4 		$29.4K Hold
28,565
– – ﹤0.01% 3473
2024
Q3 		$38.3K Hold
28,565
– – ﹤0.01% 3440
2024
Q2 		$37.1K Hold
28,565
– – ﹤0.01% 3546
2024
Q1 		$49.1K Hold
28,565
– – ﹤0.01% 3372
2023
Q4 		$42K Hold
28,565
– – ﹤0.01% 3418
2023
Q3 		$34.6K Hold
28,565
– – ﹤0.01% 3444
2023
Q2 		$41.4K Hold
28,565
– – ﹤0.01% 3441
2023
Q1 		$41.4K Hold
28,565
– – ﹤0.01% 3381
2022
Q4 		$49.4K Buy
+28,565
New +$53.3K ﹤0.01% 3364
2022
Q2 		– Sell
-65,547
Closed -$571K – 3636
2022
Q1 		$571K Hold
65,547
– – ﹤0.01% 3062
2021
Q4 		$1.05M Buy
65,547
+1,961
+3% +$31.1K ﹤0.01% 2896
2021
Q3 		$1.17M Buy
63,586
+3,090
+5% +$49.6K ﹤0.01% 2817
2021
Q2 		$845K Buy
60,496
+7,138
+13% +$99.7K ﹤0.01% 2992
2021
Q1 		$786K Buy
53,358
+1,527
+3% +$26.9K ﹤0.01% 2930
2020
Q4 		$1.01M Buy
51,831
+16,377
+46% +$255K ﹤0.01% 2767
2020
Q3 		$396K Hold
35,454
– – ﹤0.01% 2950
2020
Q2 		$480K Buy
35,454
+4,090
+13% +$45.9K ﹤0.01% 2847
2020
Q1 		$254K Buy
31,364
+4,138
+15% +$36.5K ﹤0.01% 2942
2019
Q4 		$262K Hold
27,226
– – ﹤0.01% 3002
2019
Q3 		$289K Buy
27,226
+2,108
+8% +$22.2K ﹤0.01% 2973
2019
Q2 		$290K Buy
25,118
+5,895
+31% +$71K ﹤0.01% 3024
2019
Q1 		$247K Buy
19,223
+4,696
+32% +$49.8K ﹤0.01% 2980
2018
Q4 		$90K Hold
14,527
– – ﹤0.01% 3098
2018
Q3 		$153K Buy
+14,527
New +$169K ﹤0.01% 3100

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Charles Schwab's SPRO Position: Q1 2026 in Review

Charles Schwab held its Spero Therapeutics (SPRO) position steady in Q1 2026 at 28,565 shares worth $66.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3411.

Charles Schwab first reported a position in SPRO in Q3 2018 and has held it in 29 quarters since. The position peaked at $1.17M in Q3 2021. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Charles Schwab held 28,565 shares of Spero Therapeutics worth $66.8K as of Q1 2026.
  • Charles Schwab left its Spero Therapeutics share count unchanged in Q1 2026.
  • Spero Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #3411 holding.
  • Charles Schwab first reported a position in Spero Therapeutics in Q3 2018 and has held it in 29 quarters since.
  • Charles Schwab's Spero Therapeutics position peaked at $1.17M in Q3 2021.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.